DCGO DocGo Inc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed Apr 22, 2026 Processed 1mo ago SEC 0001822359-26-000017
8-K context-dependent: Items 5.02
Latest settled — T+20d ⚠ clustered
DCGO ▼ -22.96% at T+20d
NEUTRAL call ✗ call lost -22.96% · α vs SPY -26.13% · entry $0.7360 → $0.5670
Next anchor: T+60d in 8w
Last close $0.6310 (close May 22) · -14.27% from $0.7360 entry
Entry anchored
Apr 21, 03:59 PM ET
via Databento tick
T+1d
-6.52%
call -6.52% · α -6.13%
$0.6880
settled 5w ago
T+5d
-5.71%
call -5.71% · α -5.76%
$0.6940
settled 26d ago
T+20d
-22.96%
call -22.96% · α -26.13%
$0.5670
settled 5d ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

DocGo Inc. announced the departure of board member Dr. Stephen Klasko, effective after the 2026 Annual Meeting, and the appointment of Michael Burdiek as independent Chair of the Board. A new special committee focused on cost reduction and profitability was also formed, chaired by Burdiek.

Actionable Insight

Monitor upcoming financial reports for evidence of cost-saving measures or changes in operating expenses resulting from the new special committee's work. The leadership reshuffle is routine governance but signals a board-level focus on achieving profitability.

Key Facts

  • Dr. Stephen Klasko is stepping down from the Board of Directors and committee positions effective after the 2026 Annual Meeting on June 16, 2026.
  • Dr. Klasko's departure is due to accepting a new healthcare leadership role and was not related to any disagreement with the company.
  • Michael Burdiek was appointed as independent Chair of the Board, effective at the same time.
  • Jim Travers was appointed to replace Dr. Klasko on the Audit and Compliance Committee and Nominating and Corporate Governance Committee.
  • A new special committee focused on identifying cost reduction opportunities and accelerating profitability was formed, consisting of Vina Leite, Ira Smedra, and Michael Burdiek, with Burdiek as chair, effective April 21, 2026.

Financial Impact

No direct financial impact disclosed. The formation of a special committee focused on cost reduction suggests a strategic emphasis on improving profitability.

operating expensesprofitability timeline

Risk Factors

  • Potential disruption from board leadership transition, though mitigated by planned succession.
  • The focus on cost reduction could indicate pressure on margins or slower-than-expected path to profitability.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Health Services

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001822359-26-000017
Document: 0001822359-26-000017-index-headers.html0001822359-26-000017
Document: 0001822359-26-000017-index.html0001822359-26-000017
Document: 0001822359-26-000017.txt0001822359-26-000017
4 reports for DCGO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DCGO — sortable, filterable
Type Now
May 11, 2026
12d ago
8-K
MIXED ★ 5/10
$0.5950 $0.5530▼ −7.06%▼ −7.14%$0.6310 (+6.05%)
Apr 22, 2026
4w ago
DEFA14A
NEUTRAL ★ 4/10
$0.6880 $0.7070▲ +2.76%▲ +1.28%$0.6310 (−8.28%)
Apr 22, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$0.7360 $0.6940▼ −5.71%▼ −5.76%$0.6310 (−14.27%)
Feb 28, 2026
12w ago
Institutional Cluster
BULLISH ★ 6/10
$0.6900 $0.6720▼ −2.61%▼ −1.40%$0.6310 (−8.55%)
Showing 4 of 4

US Market Status

Market Closed — Opens Tue (34h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access